Program

Clinical Trial Support

Gene Solutions is actively pursuing partnerships with leading investigators at medical centers/hospitals and biopharmaceutical companies to accelerate the future of precision oncology. ​

We’d love to hear your questions! Please feel free to submit any inquiries you may have about K-TRACK.​

ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer​

Key finding:

This is a prospective observational study, in collaboration with 3 hospitals (175 Military Hospital, Nguyen Tri Phuong Hospital, and 108 Military Central Hospital), plans to recruit 100 patients with stage II-III rectal cancer and indicated for total neoadjuvant therapy. K-TRACK assay will use to evaluate value of ctDNA in Predict the Efficacy of TNT for Rectal Cancer​.

Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer

Key finding:

This prospective and observational study, in collaboration with University Medical Center HCMC, plans to recruit 75 patients with stage II-III HER+/Triple Negative Breast cancer and indicated for neoadjuvant chemotherapy. K-TRACK assay will use aim to determine the detection rate and change of ctDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.

K-CONNECT APAC 2025